Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Kai Cenat's friend Ray H uses N-word during live stream, Internet says 'that wasn't accidental'
Smartphone Shipments on Track for Another Low in 2023: Can iPhone 15 Help?
The 32 Best Amazon Fashion Deals This Week
Save 90% on a lifetime subscription to this password manager
'No evidence' Facebook harms well-being: global study
Twitter reportedly ran family-friendly ads next to alt-right propaganda
What's Your Type? How to Add Custom Fonts on an iPhone or iPad
'Enhance Image' Function in Edge Browser Sends Image URLs to Microsoft